510(k)
K202101: GEM Hemochron 100 System, GEM Hemochron 100 Activated Clotting Time Plus Test (ACT+), GEM Hemochron 100 Low Range Activated Clotting Time Test (ACT-LR), directCHECK ACT+ Whole Blood Control, Level 1 and Level 2, directCHECK ACT-LR Whole Blood Control, Level 1 and Level 2
FDA 510(k) · Accriva Diagnostics, Inc. · decided Dec 29, 2021
Key facts
| 510(k) number | K202101 |
|---|---|
| Device name | GEM Hemochron 100 System, GEM Hemochron 100 Activated Clotting Time Plus Test (ACT+), GEM Hemochron 100 Low Range Activated Clotting Time Test (ACT-LR), directCHECK ACT+ Whole Blood Control, Level 1 and Level 2, directCHECK ACT-LR Whole Blood Control, Level 1 and Level 2 |
| Applicant | Accriva Diagnostics, Inc. |
| Product code | JPA |
| Subsequent product codes | GGN, JBP |
| Date received | Jul 29, 2020 |
| Decision date | Dec 29, 2021 |
| Decision | Substantially equivalent (SESE) |
| Submission type | Traditional |
| Review panel | Hematology |
| Medical specialty | Hematology |
At a glance
- 1–9 MAUDE adverse event reports
- 1–9 Recall events
- 1–9 UDI device identifiers (GUDID)
- 1–9 Predicate devices cited
- None Later submissions citing this device
- 100–999 510(k)s with this product code
- Yes 510(k) summary on file
- No 510(k) statement on file
- Not listed On the FDA AI-enabled device list
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
Reading a 510(k)
- Decision
- SESE means the FDA found the device substantially equivalent to its predicate, so it may be marketed in the United States.
- Predicates
- Each clearance cites one or more legally marketed devices; the chain of predicates shows where a technology came from.
- Product code
- The three-letter code sets the device type, class and regulation, and groups competing clearances.
- Summary or statement
- Applicants file either a 510(k) summary of the safety and effectiveness information or a statement that it is available on request.
About 510(k) premarket notifications
A 510(k) is a premarket submission made to the FDA to demonstrate that a device is substantially equivalent to a legally marketed predicate device.
Source: U.S. Food and Drug Administration (FDA), 510(k) Premarket Notification database · Source date: